Stephanie Sommer, PhD

Global Regulatory Affairs, Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany

JCP
BI 1358894 in Borderline Personality Disorder
Original Research

January 13, 2025

Although the primary endpoint was not met, BI 1358894 was well-tolerated with no increase in self-harm or suicidality.
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe